Neuphoria Therapeutics Inc (NEUP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Neuphoria Therapeutics Inc (NEUP) is up 14.4% since the beginning of the year. At $4 per share, NEUP is trading 79.3% below its 52-week high of $21.

Neuphoria Therapeutics Inc (NEUP) has returned 14.43% so far this year and -34.71% over the past 12 months.

Based on dividend-adjusted daily data since Dec 23, 2024, NEUP's average daily return is +6.97%, while the average monthly return is +71.39%. At this rate, an investment would double in approximately 0.1 years.

Historically, 63% of months were positive and 37% were negative. The best month was Dec 2024 with a return of +1,266.5%, while the worst month was Oct 2025 at -61.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 3 months.

On a daily basis, NEUP closed higher 49% of trading days. The best single day was Dec 24, 2024 with a return of +2,520.6%, while the worst single day was Oct 21, 2025 at -68.5%.

Neuphoria Therapeutics Inc has an annualized alpha of 801669770.56%, beta of 6.76, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 23, 2024.

• This stock captured 179.34% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -12873.41%) - a profile typical of hedging or uncorrelated assets.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NEUP ranks 38 for risk / return — below 38% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Neuphoria Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Neuphoria Therapeutics Inc was 81.40%, occurring on Dec 26, 2025. The portfolio has not yet recovered.

The current Neuphoria Therapeutics Inc drawdown is 77.80%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Neuphoria Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Neuphoria Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.